Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Xiaoting Zhang · RNA NANOTHERAPEUTICS LLC · 2023 · $55,000 — Project Summary Breast cancer is one of the most frequent cancers and leading causes of death for women in the U.S. with an estimated 287,850 new diagnoses of invasive breast cancer and 43,250 deaths in 2022. The vast majority (75%) of breast cancer is estrogen receptor-positive (ER+) breast cancer …
Julia Meghan Davis-Porada · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2023 · $49,170 — PROJECT SUMMARY Vaccines save lives, and the rapid development of novel vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was a triumph for the medical community. While the rapid deployment of these vaccines has undoubtedly attenuated the severe morbidity and mortality in…
Hao Cheng · DREXEL UNIVERSITY · 2023 · $350,000 — Project Summary The immune system protects people from pathogens. However, it sometimes generates abnormal immune reactions against harmless environmental antigens or patient’s own antigens, leading to allergy or autoimmune diseases, respectively. These hypersensitivity disorders affect millions of…
Natalie Lea Silver · CLEVELAND CLINIC LERNER COM-CWRU · 2023 · $155,304 — PROJECT SUMMARY/ABSTRACT Oral cavity squamous cell carcinoma (OCSCC) is a very aggressive and deadly disease with poor survival rates following maximal treatments such as surgery and chemoradiotherapy. The immunosuppressive tumor microenvironment (TME) is a major barrier of response to traditional …
Keith Thomas Gagnon · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2023 · $205,541 — PROJECT SUMMARY Messenger RNA, or mRNA, and its translation into protein lies at the heart of the central dogma of molecular biology. Converting this basic cellular mechanism into a therapeutic opportunity was the basis of the first two successful COVID-19 vaccines. This technology has the potentia…
Ken A Halvorsen · STATE UNIVERSITY OF NEW YORK AT ALBANY · 2023 · $249,950 — Project Summary/Abstract Our vision is to develop, apply, and advance new technologies in the broad thematic program of the manipulation of nucleic acids. The research largely focuses on RNA-based applications, which is both driven and enhanced by our unique environment at The RNA Institute, enablin…
Gregory Allan Smith · THYREOS, INC · 2023 · $297,493 — PROJECT SUMMARY There is an unmet need for a herpes simplex virus (HSV) vaccine. We propose to develop a live-attenuated HSV-2 vaccine based on our R2 technology platform. R2 vaccines show unprecedented safety and efficacy in animal models, and offer antigenicity superior to subunit/mRNA and single-…
BRIAN KELSALL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,757,182 — This project focuses on the roles of different populations of dendritic cells (DC) and macrophages (MP) in immune responses in mucosal tissues. While it is clear that the normal outcome of mucosal antigen exposure can be positive, i.e., the development of intestinal IgA and effector T cell responses…
Arya Biragyn · NATIONAL INSTITUTE ON AGING · 2023 · $447,017 — The role of aging-linked immune dysregulation in dementia and Alzheimers disease (AD) remains poorly understood. Recently we proposed that AD requires B cells. We demonstrated that AD cannot progress if B cells are lost (Kim et al., Nature Commun., 2021). Thus, in addition to the benefit (as produc…
Lothar Hennighausen · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $1,291,106 — In the current reporting period we published three COVID-19 studies, one on the limited cross-variant immune response from the Omicron BA.2 strain in nave patients (PMID: 36267551), on the vaccination of patients with Stills disease (PMID: 35532082) and the effect of vaccination of CLL leukemia pati…
Yun Xing m wang · DIVISION OF BASIC SCIENCES - NCI · 2023 · $2,215,225 — My lab has made progress on several fronts. First, we have developed a novel algorithm and a method using AFM to study RNA conformational dynamics in solution. Briefly, we are now able to directly visualize individual RNA conformers in solution and determine the structures of individual RNA molecule…
Mary N. Carrington · DIVISION OF BASIC SCIENCES - NCI · 2023 · $638,498 — HLA class I (HLA-I) allotypes vary widely in their dependence on tapasin (TAPBP), an integral component of the peptide loading complex, to present peptides on the cell surface. We have determined tapasin dependence (TD) values for common HLA-I allotypes across worldwide populations (N = 250), which …
Michael C. Abt · UNIVERSITY OF PENNSYLVANIA · 2023 · $348,154 — SUMMARY: PROJECT 3 - IMMUNOLOGY The quality of the host immune response to Clostridioides difficile infection is one of the strongest predictors of disease severity. Despite the protective capacity of the host immune response, the immune parameters that promote immunity remain poorly understood. App…
Steven James Madore · UNIVERSITY OF FLORIDA · 2023 · $43,615 — SHARED RESOURCE MANAGEMENT: ABSTRACT The University of Florida Health Cancer Center (UFHCC) members benefit from access to the UFHCC-managed Biostatistics and Quantitative Sciences Shared Resource (BQS-SR) and the institutionally-managed Flow Cytometry and Confocal Microscopy Shared Resource (CYT-SR…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $113,758 — Admin Core: Project Summary/Abstract A significant overall goal of CAP-IT is to identify and validate immunologically targeted agents for precision prevention of individuals with increased cancer risk. The CAP-IT Center for RNA Immunoprevention (CRI) Administrative Core (AC) mission is to ensure tha…
KUNLE ODUNSI · UNIVERSITY OF CHICAGO · 2023 · $226,986 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIMcGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
Barton F. Haynes · DUKE UNIVERSITY · 2023 · $2,798,848 — Abstract - Core 3 The current SARS-CoV-2 pandemic is the third major pathogenic outbreak caused by a betaCoV in the last two decades. Development of panbetacoronavirus (panbetaCoV) vaccines for group 2b and group 2c beta CoVs is a major priority of this P01. In addition, this P01 will evaluate alpha…
Barton F. Haynes · DUKE UNIVERSITY · 2023 · $1,092,131 — Abstract - Project 1 Zoonotic coronaviruses (CoV) are responsible for three major epidemics/pandemics in the 21st century, including Severe Acute Respiratory Coronavirus (SARS-CoV) in 2003 and Middle East Respiratory coronavirus (MERS- CoV) in 2012. In Dec 2019, a third novel coronavirus (CoV) desig…
Marie Pancera · FRED HUTCHINSON CANCER CENTER · 2023 · $484,694 — PROJECT SUMMARY/ABSTRACT Broadly neutralizing antibodies are likely to be an important component of an HIV-1 vaccine. The HIV-1 Envelope (Env) glycoprotein is the sole target of neutralizing antibodies and has been a focus of immunogen designs. Yet diverse recombinant (rec) Envs do not display detec…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $277,117 — SUMMARY The VIVA Clinical Core B provides the infrastructures needs to support standardized approaches for the recruitment, longitudinal retention and clinical characterization of human subjects enrolled in observational studies. The Core B will facilitate patient centered research through activitie…